Published in Semin Oncol on June 01, 2013
The strategies to control prostate cancer by chemoprevention approaches. Mutat Res (2014) 0.87
Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 in Vivo. J Cancer Ther (2014) 0.80
A novel anti‑cancer effect of resveratrol: reversal of epithelial‑mesenchymal transition in prostate cancer cells. Mol Med Rep (2014) 0.79
The role of micronutrients in the risk of urinary tract cancer. Arch Med Sci (2016) 0.78
A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review). Oncol Lett (2014) 0.76
Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis. Int J Mol Sci (2016) 0.75
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol (2009) 3.59
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Positive surgical margins in robot-assisted partial nephrectomy: a multi-institutional analysis of oncologic outcomes (leave no tumor behind). J Urol (2013) 2.76
Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet (2011) 2.51
Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst (2006) 2.48
PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol (2010) 2.33
Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev (2009) 2.20
11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med (2003) 2.16
Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med (2009) 1.94
Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci U S A (2009) 1.81
RNASEL Arg462Gln polymorphism and prostate cancer in PLCO. Prostate (2007) 1.74
Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer (2013) 1.66
Risk-based prostate cancer screening. Eur Urol (2011) 1.64
Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev (2012) 1.63
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol (2006) 1.63
A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Res (2005) 1.63
11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med (2013) 1.60
The MAPP research network: design, patient characterization and operations. BMC Urol (2014) 1.56
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int (2011) 1.54
Renal functional and perioperative outcomes of off-clamp versus clamped robot-assisted partial nephrectomy: matched cohort study. Urology (2012) 1.52
The MAPP research network: a novel study of urologic chronic pelvic pain syndromes. BMC Urol (2014) 1.47
Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA (2011) 1.46
Use of gelatin matrix to rapidly repair diaphragmatic injury during laparoscopy. Urology (2002) 1.45
Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? Urology (2013) 1.45
Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial. Urology (2009) 1.45
Robot-assisted partial nephrectomy: off-clamp technique. J Endourol (2012) 1.44
Biopsy misidentification identified by DNA profiling in a large multicenter trial. J Clin Oncol (2011) 1.44
Endopyelotomy for pediatric ureteropelvic junction obstruction: a review of our 25-year experience. J Urol (2012) 1.44
Three-Dimensional (3D) Vision: Does It Improve Laparoscopic Skills? An Assessment of a 3D Head-Mounted Visualization System. Rev Urol (2005) 1.41
Pure laparoscopic radical heminephrectomy and partial isthmusectomy for renal cell carcinoma in a horseshoe kidney: case report and technical considerations. Urology (2005) 1.39
Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of high-grade non-muscle invasive bladder cancer. Int J Urol (2012) 1.39
First 100 cases at a low volume prostate brachytherapy institution: learning curve and the importance of continuous quality improvement. Can J Urol (2013) 1.38
Live robotic surgery: are outcomes compromised? Urology (2012) 1.38
Benign prostatic hyperplasia: a progressive disease of aging men. Urology (2003) 1.31
Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev (2007) 1.30
Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. J Natl Cancer Inst (2010) 1.29
2D versus 3D visualization: impact on laparoscopic proficiency using the fundamentals of laparoscopic surgery skill set. J Laparoendosc Adv Surg Tech A (2012) 1.29
Laparoscopic partial nephrectomy for renal masses: effect of tumor location. Urology (2006) 1.27
Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J Natl Cancer Inst (2012) 1.27
Prostate cancer screening: current status and future perspectives. Nat Rev Urol (2010) 1.23
Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. Urology (2007) 1.18
Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. Hum Mol Genet (2011) 1.17
Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer (2008) 1.17
Screening for prostate cancer. BMJ (2010) 1.14
Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int (2007) 1.13
Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control (2008) 1.13
Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr (2012) 1.11
Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer. J Urol (2011) 1.11
Prostate-specific antigen-based screening: controversy and guidelines. BMC Med (2015) 1.08
Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology (2006) 1.07
Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int (2008) 1.07
Outcomes and predictors of clinical T1 to pathological T3a tumor up-staging after robotic partial nephrectomy: a multi-institutional analysis. J Urol (2013) 1.05
Polysymptomatic, polysyndromic presentation of patients with urological chronic pelvic pain syndrome. J Urol (2012) 1.04
Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity. J Urol (2009) 1.03
Serum selenium and risk of prostate cancer-a nested case-control study. Am J Clin Nutr (2007) 1.02
Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3). Hum Mol Genet (2009) 1.01
The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int (2013) 1.01
Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. Cancer Epidemiol Biomarkers Prev (2010) 0.99
Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006. Urology (2007) 0.98
Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology (2004) 0.97
Population based comparative effectiveness of transurethral resection of the prostate and laser therapy for benign prostatic hyperplasia. J Urol (2012) 0.97
Supernumerary kidney in a child with OEIS complex. Urology (2009) 0.96
Off-clamp robot-assisted partial nephrectomy preserves renal function: a multi-institutional propensity score analysis. Eur Urol (2012) 0.96
TNF polymorphisms and prostate cancer risk. Prostate (2008) 0.95
Large-scale fine mapping of the HNF1B locus and prostate cancer risk. Hum Mol Genet (2011) 0.94
The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology (2005) 0.93
Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol (2008) 0.93
Emerging drug therapies for benign prostatic hyperplasia. Expert Opin Emerg Drugs (2006) 0.93
Complications of primary and revision functional endoscopic sinus surgery for chronic rhinosinusitis. Laryngoscope (2013) 0.92
Changes in symptoms during urologic chronic pelvic pain syndrome symptom flares: findings from one site of the MAPP Research Network. Neurourol Urodyn (2013) 0.92
Gleason 6 Prostate Cancer: Translating Biology into Population Health. J Urol (2015) 0.91
Tumor complexity predicts malignant disease for small renal masses. J Urol (2012) 0.91
Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis (2007) 0.90
Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. BJU Int (2014) 0.87
Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology (2003) 0.87
Renal hypothermia achieved by retrograde endoscopic cold saline perfusion: technique and initial clinical application. Urology (2003) 0.87
Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment. J Urol (2012) 0.87
Efficacy of transcutaneous electrical nerve stimulation in children with overactive bladder refractory to pharmacotherapy. Urology (2007) 0.86
Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial. Urology (2011) 0.86
Validation of a prognostic calculator for prediction of early vesicoureteral reflux resolution in children. J Urol (2009) 0.86
Traumatic urethral injury without pelvic fracture in an adult female. ScientificWorldJournal (2010) 0.86
Managing the local complications of locally advanced prostate cancer. Curr Urol Rep (2007) 0.86
Ascertaining cause of death among men in the prostate cancer intervention versus observation trial. Clin Trials (2013) 0.85
Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ. J Urol (2011) 0.84